Mangano Katia, Dati Gabriele, Quattrocchi Cinzia, Proietti Lidia, Mazzarino Clorinda, Di Marco Roberto, Bendtzen Klaus, Greco Beatrice, Zaratin Paola, Nicoletti Ferdinando
Department of Biomedical Sciences, Section of Clinical Pathology and Molecular Oncology, University of Catania, Catania, Italy.
J Neuroimmunol. 2008 May 30;196(1-2):107-15. doi: 10.1016/j.jneuroim.2008.03.008. Epub 2008 May 2.
The immunosuppressive agent cyclophosphamide (CY) was tested in rat experimental allergic neuritis (EAN), a preclinical model of Guillain Barrè syndrome (GBS). CY prophylaxis (day 0 and 14 post-immunization [p.i.]) effectively prevents clinical and histological signs of EAN and also reduces the cytokine and the NF-kappaB p65 expression in the nervous tissue. When administered therapeutically (day 14th p.i.) to rats with established disease CY only affects the clinical symptoms. Both the prophylactic and therapeutic treatment with CY reduced ex vivo antigen-specific T cell proliferative responses. These results warrant studies with CY in those cases of GBS resistant to conventional therapies.
